Displaying publications 1 - 20 of 52 in total

  1. Tay SK, Tay YK
    Aust N Z J Obstet Gynaecol, 2009 Jun;49(3):323-7.
    PMID: 19566569 DOI: 10.1111/j.1479-828X.2009.01000.x
    To investigate the prevalence of high-risk human papillomavirus (HPV) and its associated cytological abnormalities among women attending cervical screening clinics in southern Malaysia and Singapore.
  2. Lim SS, Tan PC, Sockalingam JK, Omar SZ
    Aust N Z J Obstet Gynaecol, 2008 Feb;48(1):71-7.
    PMID: 18275575 DOI: 10.1111/j.1479-828X.2007.00808.x
    To compare oral celecoxib with oral diclofenac as pain reliever after perineal repair following normal vaginal birth.
  3. Naim NM, Mahdy ZA, Ahmad S, Razi ZR
    Aust N Z J Obstet Gynaecol, 2007 Apr;47(2):132-6.
    PMID: 17355303 DOI: 10.1111/j.1479-828X.2007.00699.x
    OBJECTIVE: To compare the effectiveness of the Vabra aspirator and the Pipelle device as an outpatient endometrial assessment tool.
    METHOD: This was a randomised, prospective trial conducted for a period of one year.
    RESULTS: A total of 147 patients were recruited, of which 71 were in the Vabra group and 76 were in the Pipelle arm. The procedure success rate in the Pipelle group was significantly higher than the Vabra arm (98.7 vs 88.7%, P=0.02). Adequate tissue yield was also significantly more in the Pipelle arm (73.3 vs 52.4%, P=0.02). Cost-benefit analysis revealed a higher average cost per patient in the Vabra group compared to the Pipelle arm.
    CONCLUSION: This study proved that the Vabra aspirator was not as effective as the Pipelle device in obtaining endometrial tissue for histological diagnosis. Despite its higher price per unit, the Pipelle device was a more cost-effective tool for outpatient endometrial assessment.
    Study site: Medical clinic, Pusat Perubatan Universiti Kebangsaan Malaysia (PPUKM), Kuala Lumpur, Malaysia.
  4. Tan PC, Subramaniam RN, Omar SZ
    Aust N Z J Obstet Gynaecol, 2007 Feb;47(1):31-6.
    PMID: 17261097
    To compare the outcome in 1000 women at term with one lower transverse Caesarean that was suitable for a trial of labour.
  5. Ho JJ, Thong MK, Nurani NK
    Aust N Z J Obstet Gynaecol, 2006 Feb;46(1):55-7.
    PMID: 16441696
    We studied 253 women with a pregnancy complicated by a birth defect and 506 controls to determine the frequency and type of prenatal tests and the types of defects detected antenatally. Most women had at least one ultrasound examination, but the frequency of other screening tests was low. Only 38 (15%) of defects were detected antenatally (37 by ultrasound). Birth prevalence is unlikely to be affected by pregnancy termination.
  6. Tan PC, Suguna S, Vallikkannu N, Hassan J
    Aust N Z J Obstet Gynaecol, 2006 Dec;46(6):505-9.
    PMID: 17116055
    To assess the relationship of ultrasound assessment for amniotic fluid, fetal weight, cervical length, cervical funneling and clinical factors on the risk of Caesarean delivery after labour induction at term.
  7. Tan PC, Jacob R, Quek KF, Omar SZ
    Aust N Z J Obstet Gynaecol, 2006 Oct;46(5):446-50.
    PMID: 16953861
    In a retrospective analysis of 192 cases of presumed hyperemesis gravidarum, there were no biochemical markers that predicted hospital readmission. There was, however, statistically significant negative predictive value in abnormal liver function tests. This could represent acute self-limited illness with a component of hepatitis as the cause for the clinical presentation, rather than hyperemesis.
  8. Lo TS, Tan YL, Cortes EF, Lin YH, Wu PY, Pue LB
    Aust N Z J Obstet Gynaecol, 2015 Dec;55(6):593-600.
    PMID: 26299981 DOI: 10.1111/ajo.12397
    To clinically and sonographically evaluate the influence of anterior vaginal mesh (AVM) surgery with concomitant mid-urethral sling surgery (MUS) for stress urinary incontinence (SUI).
  9. Lo TS, Tan YL, Cortes EF, Wu PY, Pue LB, Al-Kharabsheh A
    Aust N Z J Obstet Gynaecol, 2015 Jun;55(3):284-90.
    PMID: 26044791 DOI: 10.1111/ajo.12340
    The Food and Drug Administration has recently highlighted an increase in reported complications associated with the use of transvaginal mesh.
  10. Guzmán Rojas R, Kamisan Atan I, Shek KL, Dietz HP
    Aust N Z J Obstet Gynaecol, 2015 Oct;55(5):487-92.
    PMID: 26172410 DOI: 10.1111/ajo.12347
    Rectocele is a herniation of the anterior wall of the rectal ampulla through a defect in the rectovaginal septum causing protrusion of the posterior vaginal wall. Common symptoms include symptoms of prolapse and obstructed defecation.
  11. Yusoff NM, Abdullah WZ, Ghazali S, Othman MS, Baba AA, Abdullah N, et al.
    Aust N Z J Obstet Gynaecol, 2002 May;42(2):164-6.
    PMID: 12069143 DOI: 10.1111/j.0004-8666.2002.00164.x
    OBJECTIVES: The objectives of this study were to investigate the prevalence of factor V Leiden mutation in Malay women with recurrent spontaneous abortion and to clarify the contribution of the factor V Leiden mutation to recurrent miscarriages in these women.

    DESIGN: A prospective case control study between June 1999 and April 2000.

    SETTING: Hospital University Science of Malaysia, Kubang Kerian, Kelantan, and Maternal and Child Health Clinic, Pasir Mas, Kelantan, Malaysia.

    SAMPLES: A total of 46 Malay women with a history of three or more first or second trimester miscarriages were studied. The control group consisted of 46 parous women without obstetric complications.

    METHODS: Diagnosis of factor V Leiden mutation was made by examination of factor V Leiden allele product following Mnl I digestion of factor V Leiden alleles amplified by polymerase chain reaction.

    RESULTS: None of the 46 women with recurrent spontaneous abortion carried the mutation. Also, we found no subject carrying the factor V Leiden alleles in the control group.

    CONCLUSION: These results suggest that that there is no association between the factor V Leiden mutation and recurrent spontaneous abortion in the Malay population.
  12. Soh EB, Lim JM
    Aust N Z J Obstet Gynaecol, 1999 Aug;39(3):389-90.
    PMID: 10554965
    This is a rare case of antepartum haemorrhage arising from the nonpregnant uterus in a woman with uterine didelphys. The bleeding and subsequent passage of a decidual cast did not have any adverse effect on the ongoing pregnancy.
  13. Lim JM, Soh EB, Raman S
    Aust N Z J Obstet Gynaecol, 1995 Feb;35(1):54-5.
    PMID: 7772001
    Misoprostol seems to be a drug with many potential uses apart from the treatment of gastric and duodenal ulcers. The oral tablet appears to be effective for termination of midtrimester pregnancy when administered intravaginally. Further research should be carried out to determine its full range of action in order that the drug can be utilized to its maximum potential.
  14. Tan NH, Abu M, Woo JL, Tahir HM
    Aust N Z J Obstet Gynaecol, 1995 Feb;35(1):42-5.
    PMID: 7771998 DOI: 10.1111/j.1479-828x.1995.tb01828.x
    Transvaginal sonography was performed in 70 patients diagnosed to have placenta praevia by transabdominal sonography. The diagnosis was confirmed either by digital examination in theatre at term or operative finding at delivery. Forty-nine cases (70%) were correctly diagnosed to have placenta praevia by both modes of sonography. Transvaginal sonography ruled out placenta praevia in 12 cases (17%) thought to be placenta praevia by transabdominal ultrasound. Both transabdominal and transvaginal sonography demonstrated 'placental migration' in 4 cases (6%) which were no longer praevia at delivery. Five patients (7%) were erroneously believed to have placenta praevia by both sonographic techniques. Overall, the diagnostic accuracy of transvaginal sonography was 92.8% compared with 75.7% for transabdominal sonography. None of the subjects experienced any exacerbation of bleeding or other complications. The results suggest that transvaginal sonographic localization of the placenta is safe and superior to the transabdominal route.
  15. Eng NS, Guan AC
    Aust N Z J Obstet Gynaecol, 1997 Aug;37(3):331-4.
    PMID: 9325520
    This prospective, randomized study compared the efficacy of intravaginal misoprostol (Cytotec) and gemeprost (Cervagem) as an abortifacient for intrauterine deaths in second trimester pregnancy. Side-effects, complications and the cost-effectiveness associated with each drug were assessed. 21 out of 25 patients (84%) in the misoprostol group aborted whereas only 17 out of 25 patients (68%) in the gemeprost group aborted within 24 hours after the initiation of therapy. In the misoprostol group, the abortion rate was influenced by the gestational age with 100% abortion rate for those > 17 weeks' gestation compared to 67% for those with a gestational age of 13-16 weeks. Side-effects were rare in either group and no major complications were reported in either group. Misoprostol was definitely more cost-effective compared to gemeprost as the mean cost of inducing an abortion using misoprostol was RM 1.08 whereas that of gemeprost was RM 105. We thus concluded that misoprostol was at least as effective as gemeprost as an abortifacient for intrauterine death in second trimester pregnancy. Moreover, it was less costly, with very few side-effects.
  16. Oei PL, Ratnam SS
    Aust N Z J Obstet Gynaecol, 1998 May;38(2):141-4.
    PMID: 9653846
    The sales data of oestrogen replacement products for 8 developing countries from 1993 to 1995 were analyzed. The data from Malaysia, Pakistan, Taiwan, Thailand, Indonesia, Philippines and South Korea showed the increasing use of oestrogen replacement products. The total usage however varied widely, from only US$11,153 (Philippines in 1993) to as much as US$6,306,717 (Taiwan in 1995). In Singapore, where oestrogen replacement is an accepted and established form of therapy for the postmenopausal woman, there has been an increase in the usage of the nonoestrogen replacement products. There are multiple reasons for the increasing sales of hormone replacement products in the developing countries and these are explored in this article. In some of the developing countries, for example China and India, hormone replacement therapy has just been introduced. However, in those developing countries in which hormone replacement therapy is already available, sales figures show increasing usage. The future augurs well for hormone replacement therapy.
  17. Chandran R, Rahman H, Gebbie D
    Aust N Z J Obstet Gynaecol, 1993 Nov;33(4):437-9.
    PMID: 8179566
    This case represents a unique primary ovarian tumour consisting of malignant mucinous elements and granulosa-theca-cell elements, the histogenesis of which remains uncertain. It also underscores the need for thorough sampling of mucinous tumours in order to discover a possible coexisting, different neoplastic component.
  18. Kannan P, Raman S, Ramani VS, Jeyamalar R
    Aust N Z J Obstet Gynaecol, 1993 Nov;33(4):424-6.
    PMID: 8179560
  19. Jeyamalar R, Sivanesaratnam V, Kuppuvelumani P
    Aust N Z J Obstet Gynaecol, 1992 Aug;32(3):275-7.
    PMID: 1445144
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links